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Abstract
The availability and efficacy of recombinant deoxyribonucleic acid yeast-derived hepatitis-B vaccine,
at a price much lower than the previously available plasma-derived hepatitis-B vaccines against hepatitis-B
virus infections, motivate a new cost-benefit analysis of hepatitis-B vaccination. Spanish data were
used to calculate direct and indirect costs of hepatitis-B infection and the costs and benefits of different
vaccination strategies in defined risk groups of the Spanish population. A vaccination program will re-
duce direct expenditures for hepatitis B if the attack rate in the target population is higher than 4.9%.
If indirect costs are included, the threshold for cost saving is reduced to 0.9%. The results are sensitive
to the price of the vaccine, the duration of protection, assumptions about consequences for quality
of life, and to indirect costs.
Viral hepatitis is a major public health problem. It is an acute inflammation of the
liver caused by hepatitis-A, hepatitis-B, hepatitis-C, hepatitis-D, and hepatitis-E viruses.
Knowledge of its etiology and epidemiology is limited, mainly because of the high
incidence of asymptomatic or anicteric infections. In most countries, hepatitis is un-
derreported. Well over 50% and perhaps as much as 75% of infections with hepatitis
viruses are not diagnosed.
Viral hepatitis B is clinically the most important type, with the highest rates of
complications, morbidity, and mortality. Exposure to hepatitis-B virus (HBV) usually
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results in a self-limiting infection that may be symptomatic (with jaundice) or asymp-
tomatic (subclinical) and therefore usually goes unrecognized. The rate of resolution
to age dependent (48). In the USA 5-10% of infections do not resolve within 6 months;
these individuals become virus carriers.1 A protracted course of infection may lead
to cirrhosis of the liver or to hepatocellular carcinoma. According to a report of an
international group of experts, it is estimated that there are 200 million carriers of
HBV in the world (45).
Viral hepatitis is an occupational hazard for many health care personnel. All coun-
tries also report high rates of infection among intravenous drug abusers, prostitutes,
and homosexuals. Newborns of HBsAg carrier mothers are at high risk of infection
(vertical transmission). The staff of certain closed institutions, such as prisons, may
also be exposed to a higher risk of infection.
Hepatitis B represents a major problem in public health, especially in countries
with intermediate and high rates of prevalence of the disease. In these countries, neo-
natal and childhood infections are frequent, with an especially high risk for chronic
sequelae. In addition to its widely recognized medical and epidemiological importance,
policymakers and health economists have developed a growing awareness of the eco-
nomic burden of the disease on society (16;21;39).
The first vaccine against hepatitis B was introduced in 1982. Because of its very
high price, about US $100 per person vaccinated, cost became one of the most impor-
tant determinants of vaccination strategies. A well-timed cost-effectiveness study was
published in 1982 by Mulley et al. (31). For a summary of different cost-benefit and
cost-effectiveness studies of hepatitis-B vaccination, see Jonsson (24). Recently, a new
generation of vaccines, produced by recombinant deoxyribonucleic acid (DNA) tech-
nology, dramatically increased the availability and reduced the price of the vaccine.
This has made it necessary to reexamine existing vaccination strategies and develop
new policies. Therefore, it is timely to repeat the cost-benefit studies with new epide-
miological data and new prices. At the same time, there is a need to incorporate methodo-
logical developments in the economic evaluation of health care technologies.
The purpose of this study is to present a model for cost-benefit and cost-
effectiveness analysis of hepatitis-B vaccination and apply the model to the existing
epidemiological and economic situation in Spain. The intention is that the study will
be helpful in developing rational vaccination strategies for hepatitis-B vaccination.
COST-BENEFIT AND COST-EFFECTIVENESS OF DIFFERENT
VACCINATION STRATEGIES
In a review of the literature on benefits and costs of human vaccinations in developed
countries, Weisbrod and Huston (46) concluded that the most telling finding from
their survey was the absence of a standardized methodology for evaluating vaccina-
tion programs. They identified a number of common methodological mistakes; for
example, studies overlooked costs in the form of side effects, costs of administration
of the vaccine were undervalued, and costs of pain and suffering associated with the
disease were omitted from the study.
In this study, we incorporated the methodological standards of Weisbrod et al.
as far as available data allowed. We included reduction in health care expenditures,
reduction in indirect costs, and improved health as benefits from vaccination. We also
included the costs of patients' time even when it was difficult to give an exact price.
A general model was used for the cost-benefit estimates and applied to a major risk
group, health care personnel. The costs of screening and vaccination were identified,
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quantified, and valued. Benefits in terms of a reduction in health care costs, reduced
indirect costs, and improved health were introduced successively. Estimates of costs
and benefits were undertaken using a computerized decision model, and sensitivity
analysis was performed.
EPIDEMIOLOGY OF HBV INFECTION AND THE EFFICACY
OF VACCINATION
The prevalence of HBV markers in the unselected Spanish population has been esti-
mated between 7% and 22% (average 17%), or 2.7-8.6 (average 6.5) million people
(9;10;12;13;18;27;38). According to data from newly recruited blood donors and preg-
nant women, the prevalence of HBsAg is 0.5-2.2% (average 1.5%), a number that cor-
responds to between 200,000 and 860,000 (average 585,000) people nationwide
(8;10;12;13;18;27;38). This fraction of the population includes recent as well as chronic
infections. About 32.5 million of the Spanish population are therefore susceptible to
HBV infection.
The incidence of HBV infection in the unselected Spanish population has been
estimated at about 0.2%, or 65,000 new infections per year (8;42). One fifth, or 13,000,
of these are expected to present with jaundice. About half of all new cases occur in
under-25-year-olds, and two-thirds are encountered in the economically active strata
of the population. More precise information is obtained by estimating the incidence
of HBV infection in risk groups that have been studied in detail (9;10;ll;12;13;17;18;
27;28;38).
A synopsis of the estimated size of some segments of the Spanish population at
increased risk of HBV infection is shown in Table 1. The annual attack rate, that is,
the percentage of newly infected persons in a segment of the population per year, and
the prevalence of any marker for HBV infection are the bases for this estimate. The
attack rate is only rarely obtainable from studies in Spain; therefore, published data
from comparable populations in other countries have to be taken into account in ac-
cordance with the available information on HBV markers in the corresponding Spanish
populations. It is evident that a certain prevalence of positive markers may be attained
slowly with a relatively low annual attack rate (e.g., hemodialysis patients) or more
rapidly with a higher attack rate (e.g., hemophiliacs, drug addicts).
For health care workers (HCWs), the risk of acquiring an HBV infection depends
on their area and type of work. Only very small segments of this group may have an
annual attack rate above 2% (9). For about 30% of HCWs, an annual incidence of
1-1.5%, or around five times that of the general population, can be anticipated (8;38),
but the majority, 60% of HCWs, has an annual incidence below 1% (38).
Therefore, an average estimate of the attack rate for all HCWs in Spain should
not exceed 1%. Vaccination of subgroups of HCWs in special high-risk departments
is, however, questionable because frequent changes of personnel between departments
make such an approach complicated and inefficient. Young HCWs who are in contact
with patients or bodily fluids should be offered the vaccine irrespective of the service
on which they are working at a certain time. In order to economize on an immuniza-
tion program for HCWs, those with less than 4 years of professional activity should
not be screened before vaccination, because such a screening strategy would not be
cost-effective (9;38).
In many studies of hepatitis B in HCWs, specialized services such as hemodial-
ysis, surgery, or obstetrics may comprise a larger than average proportion of persons
with long professional experience (38) who are not readily comparable to younger control
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groups because their exposure to HBV may have been unrelated to the profession and
due rather to an increased incidence of infection in earlier decades (cohort effect).
This aspect pertains to estimates of the current incidence of HBV infections in
other risk groups as well as the general population (7). Thus, recent campaigns against
the spread of HIV promoting the safe handling of patients' bodily fluids (14), rigorous
testing and processing of all blood products for safety with respect to viral transmis-
sion, advice against sharing of needles by drug addicts, and the promotion of "safer
sex" should have an impact on the incidence of HBV infections. But since all available
data on hepatitis B originate from studies performed several years ago, the estimates
tend to be too high. This aspect must be taken into account by cost-benefit analyses.
Large-scale protection of the intimates or family members of patients with hepa-
titis B is rather cumbersome because of the need to trace and test individuals who
might have been exposed, some of whom may already be in the incubation period
of the infection. The addition of hyperimmune gamma globulin to vaccination adds
considerably to the cost of such preventive action. Furthermore, active immunization
is only needed for contacts of patients with chronic infection; the evaluation of the
indication for active and/or passive immunization has to be judged individually by
the physician of the index case. The impact of such measures on the overall incidence
of hepatitis B nationwide is questionable. Cost-benefit analyses in this group have
to take into account the high costs for administration and work time lost. As with
other sexually transmitted diseases, attempts at control are fraught with difficulties.
An important group of new cases of HBV infections are newborns of HBsAg-
positive mothers. Intrauterine infections are extremely rare. The rate of perinatal trans-
mission depends on the infectivity of the mother, which is highest in HBeAg-positive
mothers. In Spain, only about 7% of carrier mothers are HBeAg positive (18). An
estimated average risk of perinatal transmission of 25% results in about 1,000 infected
newborns per year. Carriers in Southeast Asia or Africa or drug addicts with HBV
infection have a higher rate of HBe antigenemia (50-70%) (32). A target population
of special interest in Spain are newborns of gypsy families (3;17). These estimates are
consistent with data on the prevalence of HBV markers (31%) in children of HBsAg-
positive mothers (18). The importance of HBV infections in this age group lies mainly
in the high rate of chronic infection, which helps to perpetuate endemicity (15;26;40).
A nationwide vaccination program for these newborns seems feasible, because
screening for HBsAg during pregnancy or at term could be organized in accordance
with testing of blood donors, thus reducing the costs. In addition, pre- and postnatal
care of mothers as well as ongoing vaccination programs for infants will facilitate access
to this risk group. Adding hyperimmune gamma globulin to active immunization, al-
though not required, does improve protection of perinatally exposed newborns (26).
Immunogenicity and Protection of HBV Vaccine
The immunogenicity of plasma-derived as well as recombinant HBV vaccines depends
on the age and underlying diseases of the vaccinee as well as the vaccination schedule
(41;43). After complete courses of HBV vaccination in healthy young adults, antibody
concentrations above 10 IU/L can be expected in at least 95% of the vaccinees. The
persistence of antibody levels above this threshold depends on the initial antibody titer
achieved (19). Side effects are minimal, and it is even difficult to find statistically sig-
nificant differences between vaccinated persons and those treated with placebo (41;43).
Protection from all HBV-related events, including asymptomatic seroconversion,
has been reported to be between 75% and 86% in healthy persons, depending on the
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initial antibody response (range 21-97%) (19;41;43). Some protection has even been
observed in nonresponders. HBV infections occurring in spite of vaccination take a
more benign course than those in nonvaccinated persons. Thus, the average protection
from becoming a chronic carrier has been estimated at about 90% (25-100%) (19).
The duration of protection depends on the immune response to the vaccination.
In general, immunocompetent vaccinees can expect protection from HBV infection
for at least 5 years. This is certainly a reasonable time span to work with in cost-
effectiveness analyses. For hemodialysis patients, the protection is only about half that
of normal adults.
OUTLINE OF THE MODEL
Main Assumptions
The general model includes opportunities for screening, postexposure prophylaxis, and
variations in compliance with the vaccination schedule. Because screening is manda-
tory in public vaccination programs for hepatitis B in Spain, the model starts with
a decision node for the alternatives "screen" and "not screen." The costs of a possible
infection with HBV vary according to the patient's history (not screened vs. screened,
not vaccinated vs. vaccinated, etc.), and according to the degree of severity of the clin-
ical consequences of infection.
Postexposure Prophylaxis
For unvaccinated persons, hepatitis-B vaccine series are initiated after accidental ex-
posure. If the source is positive, one dose of hepatitis-B immune globulin is also given
(1). Instead of vaccination, it is common to give one dose of HBIG immediately and
a second dose of HBIG if screening confirms that the source was positive and the victim
negative.
Saenz Gonzalez et al. (37) reported 1,980 cases of accidental exposure per 100,000
hospital employees. Screening of both source (HBsAg) and victim (HBsAg, anti-HBs,
and HBc) was undertaken, and HBIG was injected. The result of testing was that 80%
of victims and 50% of sources were negative. For zero-negative victims and positive
source, a second dose of HBIG was injected; approximately 40% of the victims fit
this scenario.
Postexposure prophylaxis with vaccination reduces the costs of screening, as only
the source is screened. It also reduces the costs for HBIG. Because the costs of one
series of vaccinations are less than one dose of HBIG, the total cost of this strategy
is lower. The expected costs for postexposure prophylaxis are 11,650 pesetas for vacci-
nation and 16,500 for prophylaxis in the screening/vaccination strategy. But discus-
sion of this method will only complicate the model and not significantly affect the
result of the analysis.
Postexposure prophylaxis is only relevant for hospital staff or other personnel in
contact with contaminated material (syringes, needles, blood, etc.).
Compliance with the Vaccination Program
Compliance with a vaccination program is dependent on the target group, the efforts
made, and the resources used to produce a high compliance. Studies of compliance
have shown that not more than 50% of the hospital staff who were screened and found
negative accepted vaccination. One reason for this could have been fear of AIDS. Now
that a genetically produced vaccine is available, there should be less fear. Therefore,
we will assume a 90% compliance for the first dose, 85% for the second, and 80%
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for the third. Sensitivity analysis will be performed with a lower rate of compliance.
For vaccination of newborns of carrier mothers, we can probably assume an even higher
compliance, close to 100%, because of the special situation in which such a program
is implemented. For high-risk patients we can also assume a high compliance rate, while
other risk groups, for example, drug addicts, can be assumed to have a rather low com-
pliance rate. Because low compliance means that there are costs without (or with re-
duced) benefits, the level of compliance is important for the cost-effectiveness of a
vaccination strategy.
We assumed that the probability of infection is reduced 20% after the first dose,
50% after a second dose, and 90% after a third dose. For persons receiving only one
dose, this is equivalent to the assumption that they, on average, have received protec-
tion for 1 year. Sensitivity analyses will be undertaken with the values 33%, 67%, and
98%, respectively.
Side Effects
When Mulley et al. (31) undertook their study, about 6,000 people had been vacci-
nated. No serious adverse effects had been reported, but they estimated that a serious
reaction would occur with a frequency of 1 in 100,000 and that 10% of serious reac-
tions would be fatal. Approximately 100 episodes of severe illness have been reported
among 750,000 vaccinees (31).
Therefore, it is reasonable to conclude that serious side effects of the vaccine have
not been underestimated. If one assumes a frequency of 1 in 100,000 for a serious
reaction, and the costs of a serious reaction to be 350,000 pesetas (US $1 = 115 pesetas),
this will add only 3.5 pesetas to the cost of vaccination.
Minor side effects, such as a transient fever or a sore arm, have occurred among
approximately 25% of both vaccine and placebo recipients participating in clinical
trials (31). The medical costs associated with these reactions are probably negligible.
However, for the sake of completeness, we calculated that 1 person in 10 with a minor
side effect will make an extra visit to a physician, which will cost 6,000 pesetas. These
complications will add 150 pesetas to the costs of vaccination. Rivera et al. (34) esti-
mated the costs of complications at 132 pesetas per vaccinated person, which accounted
for 0.9% of an estimated total vaccination cost of 14,108 pesetas.
Externalities: Reduction in the Probability of Secondary Infection
Vaccination reduces not only the probability of infection for the vaccinated person
but also the probability of other persons being infected. This benefit is important,
particularly in vaccination programs for drug addicts and for children of carrier mothers.
It is also important, but to a lesser extent, for health care workers. It was too compli-
cated to model this benefit, but it is possible to take it into account by multiplying
the costs of infection with a certain factor, for example, 1.15, if we assume that the
secondary effect is 15% of the primary effect. Another benefit of vaccination is the
prevention of delta infection. Apart from a few exceptions, delta infections occur only
in drug addicts (30).
COSTS OF VACCINATION AND SCREENING
Cost of Vaccination
Vaccination costs include three doses of vaccine, handling and administration, and
travel and time costs for the patient. A problem with costs of administration, travel,
and patients' time is that these depend on the design of the vaccination program and
the risk groups vaccinated.
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Table 2. Summary of Vaccination Costs, in Pesetas
1st dose 2nd dose 3rd dose Total
Vaccine
Administration
Side effects
Time costs3
Total
1,800
100
50
300
2,250
1,800
100
50
300
2,250
1,800
100
50
300
2,250
5,400
300
150
300
6,750
" For hospital personnel.
Costs of handling and administration vary considerably. For individual vaccina-
tions, it is reasonable to assume that the costs of administration are equal to the costs
of a physician visit. If it is a program of mass vaccination, costs will be lower, but
not negligible. Administration costs can be reduced if the vaccine is delivered in, for
example, ready-to-use syringes. This will, of course, increase the costs for the producer
of the vaccine.
The vaccination costs are shown in Table 2. Costs for administration of the vac-
cine were calculated by Rivera et al. (34) to be 189 pesetas for personnel and 15 pesetas
for material, in 1982 prices. Rivera et al. calculated direct costs of side effects at 132
pesetas.
Time and travel costs for the patient are dependent on the specific risk group.
For hospital staff, we assumed travel costs were zero, and that a maximum of 30 minutes
were lost from work for each injection.
Costs of Screening
Saenz Gonzalez et al. (37) give the following costs for screening tests: anti-HBc, 736
pesetas; anti-HBs, 637 pesetas; and HBsAg, 474 pesetas. Given the screening strategy
used in Spain (22), the average screening cost will be 952 pesetas per person screened.
Time and travel costs for patients who are screened should also be taken into account.
For health care workers, we will assume the same costs as for vaccination, 300 pesetas.
Total costs per person for screening, therefore, will be 1,250 pesetas for this risk group.
The Cost-Effectiveness of Screening in Relation to Vaccination
If one assumes that the problem of false test results can be ignored, the threshold be-
tween vaccination and screening is determined by the costs of screening and vaccina-
tion. When the prevalence of HBV markers is lower than the ratio of screening costs
to vaccination costs, vaccination will be less costly than screening. If one assumes that
the costs of vaccination are 5,850 pesetas and the costs of screening are 950 pesetas,
the ratio is 0.16. If the expected prevalence of serological markers is higher than this
ratio, screening is cost-effective; otherwise, it is not. For health care personnel, the
ratio is 1,250/6,750 = 0.19 when time costs are included.
COSTS OF HEPATITIS-B INFECTION
Modeling Acute Infection
The first distinction must be made between asymptomatic (subclinical) and clinical
cases. Clinical cases can be divided into mild, severe (icteric), and fulminant. The bound-
aries between different cases are not very strict. It may, for example, be very difficult
to separate asymptomatic and mild cases.
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0.5 Subclinical
Infection Oc~"~"~ 0.60 Mild
Figure 1. Model of acute outcome of infection.
Table 3. Probabilities for Different Chronic Outcomes of Hepatitis-B Infection
Outcome
Resolution
Carrier state
Persistent hepatitis
Active hepatitis
High
0.74
0.12
0.093
0.047
Probability
Main
0.9
0.05
0.035
0.015
Low
0.95
0.025
0.0175
0.0075
The basic probabilities are shown in Figure 1. Mild clinical hepatitis is associated
with moderate pain and/or impairment and usually requires a visit to a physician. Se-
vere symptoms can require a hospitalization. More precise assumptions about the costs
of the different acute outcomes are shown in the section on costs.
Modeling Chronic Sequelae
For chronic outcomes, we distinguish between resolution, carrier, persistent, and ac-
tive hepatitis. For fulminant hepatitis, we also include the probability of death. Proba-
bilities for different chronic outcomes are based on three different assumptions. The
first is based on the internationally accepted distribution used, for example, by Mulley
et al. (31). We then make a sensitivity analysis using data from the Spanish study by
Saenz Gonzalez et al. (37) as the high alternative for chronic outcome and newer data
from Italy (6) and Greece (35) as the low alternative. Sensitivity analysis makes it pos-
sible for us to understand the importance of the severity of the chronic outcomes for
the result of the cost-effectiveness analysis. Table 3 shows the model for chronic out-
comes with the different probabilities used.
Direct Health Care Costs
Very few studies are published about the use of health care resources after hepatitis-B
infection. This makes it necessary to calculate expected costs based on knowledge about
medical management of the disease. Treatment of patients with hepatitis-B infection
varies between physicians and hospitals. In addition, the great variability in the conse-
quences of the disease for patients makes it difficult to calculate costs of hepatitis-B
infection. The estimates in Tables 4 and 5 are based on the best information available
and relate to other estimates, such as those by Mulley et al. (31). However, they must
be viewed only as a reasonable average. We need more detailed cost studies linked to
serious epidemiological investigation in order to answer questions about the conse-
quences of hepatitis-B infection. Treatment of patients changes continuously over time
because of progress in medical knowledge and treatment methods.
There is no need to discount the costs of acute hepatitis. We assume that the cost
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Table 4. Direct Costs, in Pesetas, of Acute Hepatitis
Subclinical hepatitis 0
Anicteric hepatitis
3 visits plus biochemical investigations (7,000 x 3 = 21,000) 21,000
Icteric hepatitis 63,000
Hospitalized (25%) (0.25 x 168,000) 42,000
7 hospital days at 20,000 per day
Convalescent visits (3 X 7,000)
Postconvalescent visit, including HBsAg/anti-HBs assay
Nonhospitalized (75%) (0.75 x 28,000) 21,000
Initial physician visit, including HBsAg/anti-HBs assay
Convalescent visits (3 x 7,000)
Postconvalescent visit, including HBsAg/anti-HBs assay
Fulminant hepatitis 300,000
Fatal (70%) (0.70 x 255,000) 180,000
7 days plus intensive care and special investigations (7 x 36,500 = 255,000)
Nonfatal (30%) (0.30 x 400,000) 120,000
15 days of hospitalization at 20,000 = 300,000 plus special investigations
and follow-up
Table 5. Direct Costs, in Pesetas, of Chronic Hepatitis
Resolution 0
Carrier 54,000
Persistent 144,000
Active 470,000
of resolution is zero. For the carrier state, we can follow Mulley et al. (31) and assume
that there will be a physician visit each year plus laboratory tests with HBsAg at a
total cost of 7,000 pesetas. If one assumes that the carrier state will last an average
of 10 years, total costs will be 54,000 pesetas with a discount rate of 5%. Saenz Gon-
zalez et al. (37) estimated the annual medical costs to be 32,052 pesetas for asymptom-
atic carriers.
For persistent hepatitis, we assume an initial 3-day hospital visit for a liver biopsy
and other tests. We assume an annual physician visit plus laboratory tests:
• 3 days of hospitalization: 3 x 20,000 60,000 pesetas
• Liver biopsy 30,000 pesetas
• Total hospitalization costs 90,000 pesetas
To this we add one follow-up visit including laboratory testing discounted at 5% for
• 5 years = 4.33 x 7,000 = 30,310 pesetas
• 10 years = 7.72 x 7,000 = 54,040 pesetas
• 20 years = 12.46 x 7,000 = 87,220 pesetas
At an average follow-up period of 10 years, the total costs for persistent hepatitis is
90,000 + 54,000 = 144,000 pesetas.
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For active hepatitis, we assume the same costs as for persistent hepatitis but add
that for years 2-10, 20% of the patients have a repeated episode of hospitalization
and liver biopsy, and for years 11-20, this share increases to 40%. Total costs discounted
at 5% amount to 470,000 pesetas.
Table 5 summarizes our estimates of the direct costs of chronic hepatitis. These
estimates can be compared with Saenz Gonzalez et al.'s (37) estimates for chronic hep-
atitis (persistent plus active), which were 370,000 pesetas for the first year and 92,417
pesetas for years 2-5. Their figures are somewhat higher, but the order of magnitude
is not too different.
Indirect Costs
Indirect costs are resources lost because of morbidity and premature mortality. Be-
cause indirect costs are calculated as lost earnings, they are dependent on the age, sex,
and employment situation of each risk group. A sample of clinical cases of hepatitis
B tested showed that two-thirds of the cases were in the age-group 15-45 years (22).
Because hepatitis-B infection is most common among economically active groups,
the indirect costs of the disease can be very important. Earlier studies of costs of clin-
ical (icteric) hepatitis B have also shown that indirect costs exceed direct costs, for ex-
ample, Adler et al. (2) and Rivera et al. (34). The most detailed calculation has been
done for the United States by Schatz et al. (39). Total annual cost in the United States
is estimated at $365 million. Direct costs amount to $225 million (60%).
Total cost is equally distributed between acute and chronic costs. They assume
that an acute, nonhospitalized case is associated with, on average, a loss of 21 days
of work. Hospitalized patients lose 43 days of work. For hospital workers, it is partic-
ularly relevant to take indirect costs into account, because in this group, by definition,
100% are employed. The unemployment rate is also low, indicating that it is difficult
to substitute time lost from work with otherwise unemployed workers.
For patients in mental health hospitals, patients on hemodialysis, drug addicts,
and prisoners, the loss of productive time will probably in most cases be very low.
However, for family members of HBV carriers, and for recruits in the armed forces,
loss of productive time (or loss of training time) can be of importance.
The following estimates for indirect costs are for medical personnel only. Saenz
Gonzalez et al. (37) estimated the following number of days of sick leave due to acute
hepatitis:
• Resolution 100.5 days ± 59.5
• Carrier 93.7 days ± 31.8
• Chronic hepatitis 215.2 days ± 151.5
• Average 118.4 days ± 88.7
Rivera et al. (34) calculated indirect costs per case of hepatitis to be 631,000 pesetas,
equivalent to about 96 days lost from work at 6,569 pesetas per working day. They
calculated costs per day assuming 250 working days per year.
To relate these data to our model, we make a distinction between the first and
subsequent years. For the first year, we assume that only the symptomatic cases lose
time from work. We then assume that in subsequent years only patients with persistent
and active hepatitis lose time from work with an average of 1 and 2 weeks, respectively
(see Table 6).
Table 7 summarizes the direct and indirect costs of infection. As is shown in Table
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Table 6. Indirect Costs, in Pesetas, of Hepatitis-B Infection
First year Subsequent Total
Asymptomatic
Resolution
Carrier
Persistent
Active
Mild symptoms
Resolution
Carrier
Persistent
Active
Icteric/fulminant
Resolution
Carrier
Persistent
Chronic
Fatal
25
25
50
50
100
100
150
150
X
X
X
X
X
X
X
X
0
0
0
0
4,500 = 112,500
4,500 = 112,500
4,500 = 225,000
4,500 = 225,000
4,500 = 450,000
4,500 = 450,000
4,500 = 675,000
4,500 = 675,000
0
7
14
7
14
7
14
X
X
X
X
X
X
0
0
4,500 = 31,500
4,500 = 63,000
0
0
4,500 = 31,500
4,500 = 63,000
0
0
4,500 = 31,500
4,500 = 63,000
0
0
0
392,553a
785,106a
112,500
112,500
617,553
1,010,106
450,000
450,000
l,067,553a
1,460,106"
0
a
 Calculated for 20
Table 7. Direct
Direct costs
Indirect costs
Total
years discounted at 5%.
and Indirect Costs, in Pesetas, of Hepatitis-B Infection
Nonvaccinated
High
61,000
207,000
268,000
Main
34,000
153,000
187,000
Low
27,000
138,000
165,000
Vaccinated
Main
12,000
65,000
77,000
7, indirect costs far exceed direct costs. This is consistent with other studies from, for
example, Spain and the United Kingdom. When we compare these studies with those
in the United States, where direct and indirect costs are of the same magnitude, we
must remember that the direct costs are much higher in the United States than in Spain
and the United Kingdom.
EFFECTS ON QUALITY-ADJUSTED LIFE YEARS
Cost-benefit studies of vaccination programs have rightly been criticized for not in-
cluding a measure of health benefit (46). One way to include such a measure is to esti-
mate the effect of the vaccination program in terms of quality-adjusted life years
(QALYs). One QALY is equal to one fully healthy year of life.
If we know the effect of a vaccination program on QALYs, we can use it in two
ways. The first is as an effectiveness measure for calculations of costs per QALY. Such
a measure can be used for comparison with other programs or risk groups. Second,
we can assign a value to each QALY saved through the program. This makes it possible
to add the health benefits to the direct and indirect costs.
Our calculations are done in four stages: (a) an estimate of the effect of infection
on life expectancy; (b) an estimate of the effect of infection on quality of life; (c) an
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Figure 2. Model for calculating loss of life expectancy due to hepatitis-B infection.
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Table 8. Sensitivity Analysis for Life Expectancy after Infection for Different Assumptions
about Survival8
PSURV1
PSURV2
USURV1
USURV2
UDEATH1
UDEATH2
Life expectancy
RISK U = 0
RISK U = 20
RISK U = 30
RISK U = 40
High
0.90
0.60
40
40
30
20
39.61
0.00140
0.01318
0.00669
0.97873
Main
0.80
0.50
40
40
30
20
39.48
0.00140
0.01648
0.01338
0.96874
Low
0.70
0.40
40
40
30
20
39.35
0.00140
0.01977
0.02007
0.95876
a
 See text for explanation of assumptions.
estimate of the loss in QALYs because of infection; and (d) an estimate of the costs
of a QALY lost because of hepatitis-B infection.
The model used to estimate the number of years of life lost due to infection is
shown in Figure 2. It is assumed that the average age when infected is 35 years for
hospital personnel and that life expectancy is 40 more years. Life expectancy at 35 years
of age is 39.5 years for men and 44.8 years for women in Spain.
We made the following assumptions:
• PSURV1 = 0.80 (the probability that a mild infection does not reduce life ex-
pectancy)
• PSURV2 = 0.50 (the probability that a severe infection does not reduce life ex-
pectancy)
• USURV1 = 40
• UDEATH1 = 30 (life expectancy reduced by 10 years)
• USURV2 = 40
• UDEATH2 = 20 (life expectancy reduced by 20 years)
With these assumptions, life expectancy after infection is 39.48 years. This means a
reduction in length of life by only 1.25%. If we do a risk analysis using these assump-
tions, the number of deaths in a cohort of 100,000 infected will be: death from ful-
minant hepatitis, 140; death from cirrhosis or PHC, 2,986. This is of the same magni-
tude as has been estimated for the United States (2,500).
A sensitivity analysis with higher and lower probabilities of survival is shown in
Table 8. We also tried a quality adjustment of years of life lost, using the Rosser/Williams
(25) method of quality adjustment. The quality adjustment is made in two steps. First,
the patient's health status is classified in two dimensions, disability and distress. Then
the different "cells" in the matrix are valued on a scale where healthy = 1.0 and dead
= 0. For the full valuation matrix, see Kind et al. (25). It is extremely difficult to clas-
sify patients who have an HBV infection according to the Rosser/Williams scale. We
make the following assumptions: (a) because the acute phase is short, we do not in-
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Table 9. Utility Weights with Rating Scale (RS), Standard Gamble (SG), and Time Trade-
off (TT) for Mild and Severe Hepatitis8
United
Sweden
Meanb
States 0
0
0
Mild
.53
.66
.60
(0.
(0.
2)
2)
RS
0
0
0
Severe
.25
.34
.30
(0.2)
(0.3)
Mild
0.79
0.91
0.85
(0.
(0.
3)
1)
SG
0
0
0
Severe
.56
.60
.58
(0.4)
(0.3)
0
0
0
Mild
.86
.83
.84
(0.
(0.
.2)
1)
TT
0
0
0
Severe
.54
.58
.56
(0,
(0.
.3)
.3)
a
 Figures in parentheses are standard deviations.
b
 Used for calculations.
elude it in our quality adjustment; (b) patients with a mild chronic outcome are as-
sumed to be in state IB, with no disability but mild distress (weight 0.995); and (c)
patients with a severe chronic outcome are assumed to be in state IIB, with slight social
disability and mild distress (weight 0.986).
The reduction in QALYs caused by infection will then be, for mild chronic outcome:
• USURV1 0.995 x 40 = 39.8
• UDEATH1 0.995 X 30 = 29.8
and for severe chronic outcome:
• USURV2 0.986 X 40 = 39.44
• UDEATH2 0.986 x 20 = 19.72
The expected number of QALYs is 39.45, compared with 39.48 when no quality adjust-
ment is made. Thus, adjustment for quality of life does not significantly affect our
result. One obvious reason for this outcome is that the valuation matrix we used shows
rather small reductions in quality of life for those illness states that can be judged
relevant after a hepatitis-B infection.
Because of this, we carried out an experimental sensitivity analysis on the quality
adjustment. In Sweden and the United States, a small group of university students
(11 Swedish students and 10 U.S. students) were asked to value mild and severe hepa-
titis. The methods used were rating scale, time trade-off, and standard gamble. The
results are shown in Table 9.
The difference between these results and the results obtained with the Rosser/
Williams matrix (25) is striking. It is also interesting to note that the utility weights
implied by a rating scale are considerably lower than the weights implied by the stan-
dard gamble and time trade-off scaling methods. If we use the average utility weights
from the different methods in Table 9 (0.76 for mild and 0.48 for severe), the expected
number of QALYs in the model will be 38.35, varying still more from the 39.45 QALYs
obtained earlier with the Rosser/Williams method.
RESULTS
Our empirical estimation is for health care personnel, the largest high-risk group for
hepatitis B in Spain. We assume that vaccination is undertaken only in combination
with a screening program. We further assume that 90% of those screened and found
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to be negative will be vaccinated with one dose of vaccine. For the second dose and
third dose, compliance is reduced 5% and 10%, respectively.
The attack rate is defined for the screened (and negative) population. When no
screening is undertaken, the attack rate has to be adjusted for the proportion of the
screened population that is marker positive.
Because vaccination will protect for more than 1 year, we have entered a duration
factor D into the model. If we assume that protection lasts for 5 years, D will be given
the value 5.0. Because it is appropriate to discount future benefits, the factor D will
also be used to incorporate the discount rate in the sensitivity analysis. Costs are as-
signed to the terminal nodes; for example, a person not screened, not vaccinated, not
exposed, and not infected will end up with zero cost. A person screened and vacci-
nated with three doses of vaccine will end up with costs of 1,250 plus 6,750 pesetas,
a total of 8,000 pesetas if not infected.
Table 10 summarizes the expected medical costs per patient with and without vac-
cination. The cost per patient increases with the attack rate for both vaccinated and
unvaccinated persons. However, costs increase faster for those who are not vaccinated,
and at an attack rate of 4.9%, both alternatives cost the same. At this threshold value,
the cost of the vaccination program is just offset by savings in medical expenditures
from fewer cases being infected. The threshold value is 2.7% for the high cost of the
infection alternative and 6.3% for the low cost.
If one assumes that the rate of attack averages 1.0% for health care personnel,
the expected costs per person for screening and vaccination are 6,000 pesetas com-
pared with 1,600 pesetas if no vaccination is undertaken. This means that the net cost
for a vaccination program for all hospital personnel, 340,000 persons, is 340,000 x
(6,000 - 1,600) = 1,500 million pesetas. We will now see how sensitive our result is
to changes in some of the basic assumptions. This sensitivity analysis is summarized
in Table 11.
Discounting does not significantly change the result. However, extending the
benefits to 10 years at a 5% discount rate reduces the threshold for the attack rate
from 5.7% to 3.2%. The probability of accidental exposure does not affect the result
of the analysis, and neither does the assumption about the share of the screened popu-
lation that is found to be marker positive. If the probability of markers is less than
0.19, it is less expensive to vaccinate without prior screening.
The result is very sensitive to the cost of the vaccine. A reduction in the price of
one dose from 1,800 to 1,500 pesetas reduces the threshold for the attack rate from
4.9% to 4.4%. Improving compliance and the efficacy of the vaccine reduces the
threshold, but the sensitivity is not very high.
Table 12 shows the expected cost per patient when indirect costs are included. The
expected costs per person are 7,700 pesetas for no screening/no vaccination and 7,200
pesetas for screening/vaccination for hospital personnel at an attack rate of 1.0% and
a marker-positive rate of 20%.
These results mean that for 340,000 hospital employees, the screening/vaccina-
tion program will save 340,000 x (7,700 - 7,200) = 170 million pesetas. If the high
alternative of costs of infection is used, the threshold for the attack rate is reduced
to 0.6%. As shown in Table 11, the result is not very sensitive to the high or low esti-
mate of indirect costs. However, including indirect costs reduces the threshold for the
attack rate from 5% to 1%.
Table 13 presents the cost-effectiveness ratio measured as cost per QALY. The cost-
effectiveness ratio is calculated both excluding and including indirect costs. It is also
shown for 0% and 5% discount rates. The cost per QALY increases when the risk
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Table 11. Sensitivity Analysis for the Attack Rate: Main Alternative for Cost of Infection
Variable Threshold for attack rate (%)
Period of protection (yr)
5 5.7
10 3.2
Discounting rate (%)
0 4.9
5 5.7
Probability of accidental exposure (%)
0 5.2
1 5.0
2 4.9
3 4.8
4 4.7
Probability of positive marker (%)
10 4.8
20 4.9
30 5.0
40 5.2
Compliance (%)
100 4.87
80 4.93
50 5.05
Vaccine efficacy (%)
90 4.93
98 4.74
Price for one dose of vaccine (pesetas)
2,100 5.5
1,800 4 9
1,500 4.4
1,200 3.8
900 3 3
600 . . 2.8
300 2.2
of infection is reduced. The gross domestic product (GDP) per capita in Spain is about
750,000 pesetas. If one assumes that the decision maker values an extra QALY at 750,000
pesetas, risk groups with an attack rate of 0.35% or higher should be vaccinated, if
we include both direct and indirect costs and discount at 5%. If only direct costs are
counted, the threshold is about 0.5%. We also performed a sensitivity analysis on cost
per QALY using the utility weights implied by the experiment illustrated in Table 9.
The cost per QALY is extremely sensitive to the method chosen for quality adjust-
ment. Our experimental data on quality adjustment implies a cost per QALY at only
about a third of that obtained with the Rosser/Williams method (25). If one assumes
again that the decision maker values an extra QALY at 750,000 pesetas, risk groups
with an attack rate of approximately 0.15% or higher should be vaccinated.
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Table 13. Cost, in Pesetas at 5% Discount Rate, per QALY at Different Attack Rates
Attack rate (%)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Direct
Rosser/
Williams (25)
3,500,000
1,800,000
1,200,000
900,000
700,000
570,000
480,000
410,000
360,000
320,000
Cost
cost only
Jonsson et al
1,200,000
600,000
400,000
300,000
230,000
190,000
160,000
140,000
120,000
110,000
per QALY
Direct plus
Rosser/
Williams (25)
3,200,000
1,500,000
900,000
590,000
400,000
270,000
180,000
110,000
60,000
18,000
indirect costs
Jonsson et al.
1,100,000
500,000
200,000
200,000
130,000
91,000
63,000
38,000
20,000
6,000
DISCUSSION
Cost-benefit and cost-effectiveness studies of vaccination against hepatitis-B have gener-
ally included only medical costs (20;31). This restriction can be defended if the deci-
sion maker's main interest is to know how the program affects the health budget. How-
ever, most countries do not have a single health budget; vaccination programs are usually
funded separately from medical services. The decision maker in charge of vaccina-
tions cannot benefit from calculated savings in health care costs that are due to fewer
infections. This fact means that the usual approach to cost-benefit analysis is consis-
tent neither with incentives for cost minimization nor with the relevant concept of
social cost. Only in situations where savings in health care costs can be assumed to
correspond to a minimum value of health improvement that exceeds the cost of preven-
tion can a study be used for conclusions about the net social value of the program.
Ideally, such a study should also take into account the savings in other preventive ex-
penditures due to the protection given by the vaccination. However, since preventive
measures against hepatitis-B infection are the same as those against HIV, this has no
practical significance in this case. For a more detailed discussion about the relation
between cost saving and social benefit, see Berger et al. (5).
The cost-saving approach to prevention has a legitimate place in economic evalu-
ation when the decision maker is looking for different alternatives for containing health
care expenditures. Ideally, such an approach should also take into account effects on
health care expenditures from changes in probabilities of other diseases. However, such
financial studies are not a substitute for social cost-benefit studies.
Studies of the economic costs of hepatitis B have revealed that indirect costs due
to loss of production are a significant part of the direct costs of hepatitis B. It seems
natural to include these costs in a more comprehensive measure of the social cost of
hepatitis-B infections and the benefits of vaccination.
This study shows that inclusion of indirect costs reduces the threshold for vacci-
nation from a 5% to 1% risk of infection for the largest risk group, hospital personnel.
Because the expected attack rate in this high-risk group is estimated to be 1.5%, the
inclusion of indirect costs has a significant effect on the outcome of the study.
Direct and indirect costs underestimate the true social costs of hepatitis-B infec-
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tion. A measure of health benefit should be included in the estimation. We estimated
the increase in QALYs from the vaccination program. This makes it possible to calcu-
late net cost per QALY at different risks of infection. Vaccination programs against
hepatitis B can then be compared with other interventions that improve the health
of the population (44;47).
Ideally, estimates of improvement in quantity and quality of life should be based
on data from controlled trials for different risk groups. Lack of such data makes it
necessary to make approximations. However, we think it is better to include the best
available estimates than to disregard health benefits. There is a need for more careful
studies of the quality of life of patients suffering from chronic sequelae of hepatitis-B
infections.
Russell (36) has pointed out that including both the value of improved health and
increased earnings results in counting some health effects twice. While this is a valid
point, it has to be qualified. First, the major health benefit from the vaccination pro-
gram is an increase in life expectancy. Because we have not counted any indirect costs
due to reduced mortality, this measure counts nothing twice. Second, the degree of
double counting depends on how quality of life has been adjusted. We cannot rule
out the possibility that the weights in the Rosser/Williams matrix (25) are influenced
by opportunities to earn income. However, the existence of health insurance and cash
benefits in case of sickness or disability makes it reasonable to assume that respon-
dents take only limited account of the effect of their health status on their income
when asked to state their preferences for different health states. When performing the
valuation experiment, the students were instructed to value "pure" health effects and
not include the value of extra earnings. Therefore, we argue that taking indirect costs
into account in this study does not imply any double counting.
CONCLUSIONS
Cost and benefits from vaccination against hepatitis B depend on epidemiological,
clinical, and economic factors that show significant variation between risk groups and
over time. Therefore, a generally applicable computer model was developed as a tool
for decision making. The model allows easy changes in basic assumptions as well as
opportunities for sensitivity analysis for uncertain variables.
Estimates were undertaken for health care personnel, the major risk group for
hepatitis B in Spain. The benefits from vaccination included reductions in direct and
indirect costs from fewer infections as well as improvements in length and quality of life.
The result shows the importance of including not only savings in medical expendi-
tures but also reductions in indirect costs in the estimate of benefit. A vaccination
program will reduce the total health care expenditures for hepatitis B only if the attack
rate is higher than 4.9%. However, if reductions in indirect costs are included, the
threshold for the attack rate is reduced to 0.9%, which is below the estimated average
risk of infection of 1.0%.
Calculating the gross and net cost per QALY makes it possible to compare vacci-
nation against hepatitis B with other preventive and curative health investments. If
one assumes that the decision maker is prepared to use resources for prevention if the
cost of producing 1 QALY is less than the average GDP, all hospital personnel with
a higher risk than 0.35% should be vaccinated.
NOTE
1
 Chronic virus carrier = person who remains actively infected with HBV for more than 6
months.
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